We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TCBI:NASDAQTexas Capital Bancshares, Inc. Analysis

Data as of 2026-05-04 - not real-time

$100.85

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Texas Capital Bancshares delivered a strong Q1 2026 earnings beat, posting $1.58 EPS versus the $1.42 consensus and a 63% YoY surge in net income to $69.5 million. Revenue grew 17% year‑over‑year, while operating and profit margins sit at robust 32% and 28.7% respectively, underscoring solid profitability. The stock trades at $100.85, just above the 30‑day support of $96.35 and marginally below the 20‑day SMA of 101.66, indicating a price near a technical floor but still within the bullish trend band defined by the 50‑day (97.30) and 200‑day (91.64) averages. Volume is on an upward trajectory, and the RSI of 52 signals a neutral stance, though the MACD histogram remains negative, hinting at short‑term downside pressure.
Valuation appears attractive: the forward PE of 12.0 is well under the industry average of 17.5, and the price‑to‑book of 1.34 reflects a modest premium to book value. Analysts project a median target of $107, implying roughly 6% upside, while the DCF model suggests a far higher fair value, highlighting potential undervaluation. The dividend yield of 0.79% is modest but payable from a cash pile of $2.9 billion, supporting sustainability. Risks include elevated 30‑day volatility (≈25%), a beta above 1, and sector‑specific credit and regulatory headwinds, yet the balance sheet’s low leverage and strong cash generation mitigate downside concerns.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Recent earnings beat and strong profit margins
  • Price hovering near technical support with bearish MACD signal
  • Elevated short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward PE below industry average indicating value
  • Revenue growth of ~17% and expanding operating cash flow
  • Analyst price target suggesting ~6% upside

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong balance sheet with low leverage and ample cash
  • Sustainable dividend supported by cash generation
  • Potential sector recovery and long‑term DCF upside

Key Metrics & Analysis

Financial Health

Revenue Growth16.90%
Profit Margin28.67%
P/E Ratio13.6
ROE10.15%
ROA1.10%
P/B Ratio1.3
Op. Cash Flow$447.3M
Industry P/E17.5

Technical Analysis

TrendBullish
RSI52.4
Support$96.35
Resistance$106.82
MA 20$101.66
MA 50$97.30
MA 200$91.64
MACDBearish
VolumeIncreasing
Fear & Greed Index88.63

Valuation

Fair Value$238.24
Target Price$107.38
Upside/Downside6.48%
GradeUndervalued
TypeGrowth
Dividend Yield0.79%

Risk Assessment

Beta1.20
Volatility24.78%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.